Center for Global Health R&D Policy Assessment

There’s a lot of buzz about the potential for collaborative approaches to R&D to speed up product development timelines, bring fresh ideas to the table, and cast more attention on diseases of the poor. But what is collaborative R&D exactly? Who’s doing it and why? Is open source the same as crowdsourcing?

The Center recently launched a web-based primer that is a starting point in answering some of these questions and laying out different approaches to collaborative R&D in health.

Last year, the Center for Global Health R&D Policy Assessment explored non-communicable diseases (NCDs) as it was coming out of the public health woodworks.

The George Washington University Center for Global Health and the Results for Development Institute present:

The State of Global NCDs: One year after the UN High Level Meeting

One year following the September 2011 United Nations High Level Meeting on Noncommunicable Diseases, what has been accomplished? Join us and a panel of key experts to discuss progress, gaps, and priorities for advancing measurable progress against NCDs globally.

Monday, November 12, 2012
12:30 – 2:00 pm
The George Washington University
Center for Global Health

The Center for Strategic and International Studies and the Results for Development Institute invite you to:

Research and Development for Global Health: The Contributions of Brazil, China, and India

Monday, November 5, 2012
10:00 am – 12:00pm (EST)
Center for Strategic and International Studies, B1 Conference Center
1800 K Street NW
Washington, D.C., 20006

The recent news that the Government of India has formalized an international assistance program mirrors a wider trend in the country—philanthropic giving is on the rise.* Private industry is no exception, and corporate social responsibility (CSR) programs and foundations have become common additions to firms.

The Indian biotechnology and pharmaceutical industries face a rapidly evolving policy environment. Recent changes in the intellectual property regime, price controls, debates about compulsory licensing and other discussions of access to medicines place Indian firms squarely in the global eye. In the midst of this international attention, Indian firms have continued to be important players in providing low-cost access to medicines and other technologies needed around the world and are now focusing on expanding their reach to new products and regions.

EVENT: R&D to Meet the Health Needs of Developing Countries
A discussion on the WHO CEWG and its recent report on global health research and development

Monday, May 7, 2012
11:30 am – 2:00 pm
Results for Development Institute
1100 15th St., NW, Suite 400

Are you interested in how the development and introduction of new vaccines, drugs, diagnostics and related technologies can improve health outcomes? Do you have thoughts on how to drive innovation and global health R&D for the poor? The Center for Global Health Research and Development (R&D) Policy team is looking for talented writers and bloggers like you to contribute thought-provoking entries to healthresearchpolicy.org.

This is a joint post with Edith Han.

In the past few decades, there has been significant progress in malaria control. Coverage of bednets, spraying, and other prevention commodities has increased dramatically, but ensuring access to effective and affordable treatment has remained a challenge.

In thinking about neglected disease technologies, we often overlook the specialized needs of pediatric patients. Advocacy groups have done an excellent job in illuminating the gaps in appropriate pediatric ARVs, but what about other disease areas? And what are the obstacles in developing the right neglected disease technologies for children more broadly? After a little digging, a few important issues came forward.

New Technologies. There is undoubtedly a need for new neglected disease technologies for children, especially in diagnostics.